Free tool
FAERS Monitor: Bkemv
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761333 or its brand name (Bkemv, Eculizumab-Aeeb). Reports on generic versions are filed under their own applications.
Reports
11
Serious
8
73% of reports
Hospitalization
5
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death2
- arthropathy1
- fatigue1
- gallbladder operation1
- gastrointestinal haemorrhage1
- hospitalisation1
- muscle discomfort1
- off label use1
- premature baby1
- product use in unapproved indication1
- rash1
- renal transplant1
- septic shock1
- tendon discomfort1
- unevaluable event1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 1 |
| 2026 | 10 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,148 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| tendon discomfort | 1 | 2538.5 | 391.2 | 633 |
| muscle discomfort | 1 | 2441.3 | 376.2 | 609 |
| renal transplant | 1 | 529.5 | 81.7 | 131 |
| gallbladder operation | 1 | 472.6 | 72.9 | 117 |
| premature baby | 1 | 63.5 | 9.8 | 15 |
| septic shock | 1 | 44.0 | 6.8 | 10 |
| arthropathy | 1 | 34.4 | 5.3 | 8 |
| unevaluable event | 1 | 25.3 | 3.9 | 5 |
| gastrointestinal haemorrhage | 1 | 22.9 | 3.5 | 5 |
| hospitalisation | 1 | 12.4 | 1.9 | 2 |
| product use in unapproved indication | 1 | 7.7 | 1.2 | 1 |
| death | 2 | 4.4 | 1.3 | 3 |
| rash | 1 | 4.4 | 0.7 | 0 |
| fatigue | 1 | 2.5 | 0.4 | 0 |
| off label use | 1 | 2.2 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.